Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Går Novo Nordisk op i sine medarbejderes ve og vel? Ikke når det kommer til bygningsarbejdere åbenbart. For på trods af ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Har Novo Nordisk virkelig paralyseret Kalundborgs demokrati med fortællingen om grøn vækst, erstatningsnatur og technofiks? Måske er Novo blevet for stor til Danmark ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Den danske medicinalgigant Novo Nordisk er svær at komme uden om, når man kigger på årsagerne til, at det går godt for dansk ...

Det fremgår af det årsregnskab, som Novo Nordisk har aflagt onsdag morgen. Af det store salg landede 100 milliarder på ...